• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    9/25/24 6:00:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email
    SC 13G 1 nea18-zenas_18883.htm NEA 18 VENTURE GROWTH EQUITY, L.P. -- ZENAS BIOPHARMA, INC. 13G

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    _____________________

     

    SCHEDULE 13G

    _____________________

     

    Under the Securities Exchange Act of 1934

    (Amendment No.      )*

     

     

     

     

     

    Zenas BioPharma, Inc.

     

    (Name of Issuer)

     

     

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

     

    98937L105

     

    (CUSIP Number)

     

     

     

                                         September 16, 2024                                     

    (Date of Event Which Requires Filing of this Statement)

     

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐  Rule 13d-1(b)

    ☒  Rule 13d-1(c)

    ☐  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

    CUSIP No.  98937L105

    13G Page 2 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    NEA 18 Venture Growth Equity, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     
     

    CUSIP No.  98937L105

    13G Page 3 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    NEA Partners 18 VGE, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       
     
     

    CUSIP No.  98937L105

    13G Page 4 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    NEA 18 GP VGE, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     
     

    CUSIP No.  98937L105

    13G Page 5 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Ali Behbahani

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       
     
     

    CUSIP No.  98937L105

    13G Page 6 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Carmen Chang

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     
     

    CUSIP No.  98937L105

    13G Page 7 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Anthony A. Florence, Jr.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     
     

    CUSIP No.  98937L105

    13G Page 8 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Mohamad Makhzoumi

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       


     
     

    CUSIP No.  98937L105

    13G Page 9 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Edward T. Mathers

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       
     
     

    CUSIP No.  98937L105

    13G Page 10 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Scott D. Sandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       
     
     

    CUSIP No.  98937L105

    13G Page 11 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Paul E. Walker

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       
     
     

    CUSIP No.  98937L105

    13G Page 12 of 21 Pages    

    1  

    NAME OF REPORTING PERSONS

     

    Rick Yang

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH:
     

     5

     

    SOLE VOTING POWER

     

    0 Shares

     

      6  

    SHARED VOTING POWER

     

    2,613,948 Shares

     

      7  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      8  

    SHARED DISPOSITIVE POWER

     

    2,613,948 Shares

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,613,948 Shares

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    6.6%

     

       

     12

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     
     

    CUSIP No. 98937L105

    13G Page 13 of 21 Pages    

     

     

    Item 1(a).Name of Issuer:

     

    Zenas BioPharma, Inc.

     

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    1000 Winter Street, North Building, Suite 1200, Waltham, MA 02451.

     

    Item 2(a).Names of Persons Filing:

     

    NEA 18 Venture Growth Equity, L.P (“NEA 18 VGE”); NEA Partners 18 VGE, L.P. (“NEA Partners 18 VGE”), which is the sole general partner of NEA 18 VGE; NEA 18 GP VGE, LLC (“NEA 18 VGE LLC”), which is the sole general partner of NEA Partners 18 VGE; and Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Mohamad Makhzoumi (“Makhzoumi”), Edward T. Mathers (“Mathers”), Scott D. Sandell (“Sandell”), Paul E. Walker (“Walker”) and Rick Yang (“Yang”) (together, the “Managers”).

     

    The persons named in this Item 2(a) are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

     

    Item 2(b).Address or Principal Business Office or, if None, Residence:

     

    The address of the principal business office of NEA 18 VGE, NEA Partners 18 VGE, NEA 18 VGE LLC and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Behbahani, Chang, Makhzoumi, Walker and Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence and Mathers is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.

     

     

    Item 2(c).Citizenship:

     

    NEA 18 VGE and NEA Partners 18 VGE are limited partnerships organized under the laws of the State of Delaware. NEA 18 VGE LLC is a limited liability company organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.0001 par value per share (“Common Stock”).

     

     

    Item 2(e).CUSIP No.:

     

    98937L105.

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     

     
     

    CUSIP No. 98937L105

    13G Page 14 of 21 Pages    

     

     

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    (i)NEA 18 VGE is the record owner of 2,613,948 shares of Common Stock as of September 16, 2024 (the “NEA 18 VGE Shares”). As the sole general partner of NEA 18 VGE, NEA Partners 18 VGE may be deemed to own beneficially the NEA 18 VGE Shares. As the sole general partner of NEA Partners 18 VGE, NEA 18 VGE LLC may be deemed to own beneficially the NEA 18 VGE Shares. As the individual managers of NEA 18 VGE LLC, each of the Managers also may be deemed to own beneficially the NEA 18 VGE Shares.

     

    (ii)By virtue of their relationship as affiliated entities, whose controlling entities have overlapping individual controlling persons, each of NEA 18 VGE, NEA Partners 18 VGE and NEA 18 VGE LLC may be deemed to share the power to direct the disposition and vote of the NEA 18 VGE Shares.

     

    (b)Percent of Class: See Line 11 of cover sheets. The percentages set forth on the cover sheet for each Reporting Person are calculated based on 39,792,381 shares of Common Stock reported by the Issuer to be outstanding as of September 16, 2024 upon the closing of the Issuer’s initial public offering, as reported on its prospectus filed under Rule 424(b)(4) filed with the Securities and Exchange Commission on September 12, 2024.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See Line 5 of cover sheets.

     

    (ii)shared power to vote or to direct the vote: See Line 6 of cover sheets.

     

    (iii)sole power to dispose or to direct the disposition of: See Line 7 of cover sheets.

     

    (iv)shared power to dispose or to direct the disposition of: See Line 8 of cover sheets.

     

    Each Reporting Person disclaims beneficial ownership of such Securities except for the shares, if any, such Reporting Person holds of record.

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

     

     

     
     

    CUSIP No. 98937L105

    13G Page 15 of 21 Pages    

     

     

     

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable. The Reporting Persons expressly disclaim membership in a “group” as used in Rule 13d-5(b).

     

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     

    Item 10.Certification.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    Material to be Filed as Exhibits.

     

    Exhibit 1 – Agreement regarding filing of joint Schedule 13G.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

    CUSIP No. 98937L105

    13G Page 16 of 21 Pages    

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated:   September 25, 2024

     

     

     

    NEA 18 VENTURE GROWTH EQUITY, L.P.

     

    By:NEA PARTNERS 18 VGE, L.P.
    General Partner

     

    By:NEA 18 VGE GP, LLC
    General Partner

     

    By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

     

    By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

     

     

     

    NEA PARTNERS 18 VGE, L.P.

     

    By:NEA 18 VGE GP, LLC
    General Partner

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

     

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

    NEA 18 VGE GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

     

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

     
     

    CUSIP No. 98937L105

    13G Page 17 of 21 Pages    

     

     

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Edward T. Mathers

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Paul Walker

     

     

                     *                        

    Rick Yang

     

     

     

     

    */s/ Zachary Bambach                    

    Zachary Bambach

    As attorney-in-fact

     

    This Schedule 13G was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

     

     

     
     

    CUSIP No. 98937L105

    13G Page 18 of 21 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Zenas BioPharma, Inc.

     

    EXECUTED this 25th day of September, 2024.

     

     

     

    NEA 18 VENTURE GROWTH EQUITY, L.P.

     

    By:NEA PARTNERS 18 VGE, L.P.
    General Partner

     

    By:NEA 18 VGE GP, LLC
    General Partner

     

    By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

     

    By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

     

     

     

    NEA PARTNERS 18 VGE, L.P.

     

    By:NEA 18 VGE GP, LLC
    General Partner

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

     

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

    NEA 18 VGE GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

     

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     
     

    CUSIP No. 98937L105

    13G Page 19 of 21 Pages    

     

     

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Edward T. Mathers

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Paul Walker

     

     

                     *                        

    Rick Yang

     

     

     

     

    */s/ Zachary Bambach                     

    Zachary Bambach

    As attorney-in-fact

     

     

    This Agreement was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

     

     

     

     
     

    CUSIP No. 98937L105

    13G Page 20 of 21 Pages    

     

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

     

     

     

     

     

     
     

    CUSIP No. 98937L105

    13G Page 21 of 21 Pages    

     

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

      

      

     

    Get the next $ZBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$27.00Buy
    Citigroup
    More analyst ratings

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

    - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

    9/2/25 7:05:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

    WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September: Citi's 2025 Biopharma Back to School Conference on Tuesday, September 2, 2025, at 1:00 p.m. ETCantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 8:35 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 7:45 a.m. ET Live webcasts and archived

    8/26/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Zenas Biopharma with a new price target

    Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

    3/20/25 8:00:59 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Zenas Biopharma with a new price target

    Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

    2/4/25 7:13:29 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

    H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

    12/16/24 6:47:20 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

    SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

    9/8/25 11:46:16 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

    9/2/25 7:15:16 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Zenas BioPharma Inc.

    S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

    8/12/25 8:02:03 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Nunn Jason Raleigh

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    6/12/25 4:58:46 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Fox Jennifer A.

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    6/12/25 4:38:35 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Oliveira Orlando

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    6/12/25 4:37:27 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

    4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

    4/28/25 7:07:52 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/19/25 4:01:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/11/25 4:20:30 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

    WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

    4/7/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

    –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

    3/17/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

    - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

    9/2/25 7:05:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    11/12/24 10:40:28 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    10/21/24 4:18:16 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    9/25/24 6:00:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care